Skip to main content Accessibility help
×
Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-18T17:04:14.095Z Has data issue: false hasContentIssue false

Chapter 8 - Immunotherapies for Depression

Published online by Cambridge University Press:  02 September 2021

Golam Khandaker
Affiliation:
University of Cambridge
Neil Harrison
Affiliation:
Cardiff University Brain Research Imaging Centre (CUBRIC)
Edward Bullmore
Affiliation:
University of Cambridge
Robert Dantzer
Affiliation:
University of Texas, MD Anderson Cancer Center
Get access

Summary

In relation to inflammation, the real world of people living with depressive symptoms is diagnostically divided in two. On one side of the line is the large group of patients who have depressive and other mental health symptoms associated with physical health disorders, like rheumatoid arthritis, inflammatory bowel disease or psoriasis (1; 2; 3). These are typically categorized as cases of ‘comorbid’ depression, induced by the demoralizing effects of physical illness and its treatment, and the patient’s mental reflection on the implications of their physical disease. They cannot be formally diagnosed as cases of major depressive disorder (MDD) because the standard DSM criteria for MDD explicitly exclude cases associated with a medical disorder. On the other side of this diagnostic fault line is another large group of patients with depressive symptoms that are not associated with a major medical disorder and are therefore eligible for a diagnosis of MDD (4). One of the interesting aspects of an immune strategy for new antidepressant interventions is that it cuts across this categorical distinction between comorbid depression and MDD: It offers a potentially interesting way forward for depression caused by inflammation – ‘inflamed depression’ – whether there is an obvious medical disorder with potentially very high levels of innate immune system activation in comorbid depression, or low-grade inflammation detectable only by a biomarker or blood test in a subset of patients with MDD.

Information

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×